At a glance, the 2023-24 U.S. News & World Report ranking for Best Hospitals for Cancer looks the way it always has—a list of premier institutions. You have to dig deeper to find changes in the way the closely watched 40-year-old ranking was put together and why these changes in methodology were made.
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
